Amisulpride versus other atypical antipsychotics for schizophrenia

Area of Science:

• Psychiatry and Psychopharmacology
• Evidence-Based Medicine
• Clinical Trial Analysis

Background:

• Second-generation antipsychotics (SGAs) are frontline treatments for schizophrenia globally.
• Debate exists regarding the comparative efficacy and tolerability of different SGAs.
• Amisulpride is one such SGA whose comparative profile warrants examination.

Purpose of the Study:

• To systematically evaluate the efficacy and tolerability of amisulpride versus other SGAs.
• Focus on schizophrenia and schizophrenia-like psychoses.
• Identify differences in treatment effects among SGAs.

Main Methods:

• Conducted a systematic search of the Cochrane Schizophrenia Group Trials Register (up to April 2007).
• Included randomized, at least single-blind trials comparing oral amisulpride with other oral SGAs (aripiprazole, clozapine, olanzapine, quetiapine, risperidone, sertindole, ziprasidone, zotepine).
• Employed intention-to-treat analysis with random effects models for continuous and dichotomous data.

Main Results:

• Ten trials (1549 participants) compared amisulpride with olanzapine, risperidone, and ziprasidone.
• Amisulpride showed similar efficacy to olanzapine and risperidone, but superior efficacy to ziprasidone.
• Amisulpride was associated with less weight gain than olanzapine and risperidone; olanzapine increased glucose levels more.

Conclusions:

• Limited randomized evidence exists comparing amisulpride with other SGAs.
• Amisulpride may offer advantages in tolerability (weight gain) over olanzapine and risperidone.
• Current data are based on few, short-to-medium term studies, precluding definitive conclusions.